.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Argus Health
AstraZeneca
Farmers Insurance
Teva
Novartis
Daiichi Sankyo
Cantor Fitzgerald
Harvard Business School

Generated: September 20, 2017

DrugPatentWatch Database Preview

OXAYDO Drug Profile

« Back to Dashboard

What is the patent landscape for Oxaydo, and what generic Oxaydo alternatives are available?

Oxaydo is a drug marketed by Egalet Us Inc and is included in one NDA. There are six patents protecting this drug.

This drug has eleven patent family members in five countries.

The generic ingredient in OXAYDO is oxycodone hydrochloride. There are seventeen drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the oxycodone hydrochloride profile page.

Summary for Tradename: OXAYDO

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list14
Patent Applications: see list5,607
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OXAYDO at DailyMed

Pharmacology for Tradename: OXAYDO

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Egalet Us Inc
OXAYDO
oxycodone hydrochloride
TABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► SubscribeY ► Subscribe
Egalet Us Inc
OXAYDO
oxycodone hydrochloride
TABLET;ORAL202080-002Jun 17, 2011RXNoNo► Subscribe► SubscribeY ► Subscribe
Egalet Us Inc
OXAYDO
oxycodone hydrochloride
TABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► SubscribeY ► Subscribe
Egalet Us Inc
OXAYDO
oxycodone hydrochloride
TABLET;ORAL202080-002Jun 17, 2011RXNoNo► Subscribe► SubscribeY ► Subscribe
Egalet Us Inc
OXAYDO
oxycodone hydrochloride
TABLET;ORAL202080-002Jun 17, 2011RXNoNo► Subscribe► SubscribeY ► Subscribe
Egalet Us Inc
OXAYDO
oxycodone hydrochloride
TABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► SubscribeY ► Subscribe
Egalet Us Inc
OXAYDO
oxycodone hydrochloride
TABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► SubscribeY ► Subscribe
Egalet Us Inc
OXAYDO
oxycodone hydrochloride
TABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► SubscribeY ► Subscribe
Egalet Us Inc
OXAYDO
oxycodone hydrochloride
TABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► SubscribeY ► Subscribe
Egalet Us Inc
OXAYDO
oxycodone hydrochloride
TABLET;ORAL202080-002Jun 17, 2011RXNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: OXAYDO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,476,402Methods and compositions for deterring abuse of opioid containing dosage forms► Subscribe
8,822,489Abuse deterrent compositions and methods of making same► Subscribe
8,101,630Extended release opioid abuse deterrent compositions and methods of making same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OXAYDO

Country Document Number Estimated Expiration
Israel175863► Subscribe
Israel221018► Subscribe
Australia2013206525► Subscribe
European Patent Office2420225► Subscribe
Australia2010200979► Subscribe
World Intellectual Property Organization (WIPO)2005053587► Subscribe
Australia2015264950► Subscribe
Australia2004294953► Subscribe
Canada2547334► Subscribe
European Patent Office1694260► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OXAYDO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Moodys
Teva
Deloitte
US Department of Justice
Harvard Business School
Colorcon
Argus Health
Boehringer Ingelheim
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot